Current Cardiology Reviews最新文献

{"title":"Comparison of Different Double-Stent Implantation Techniques on Coronary Bifurcation Lesions: A Finite Element Analysis.","authors":"Hongshuai Cao, Heng Wu, Jingang Zheng, Jingyi Ren","doi":"10.2174/011573403X404659250702080410","DOIUrl":"https://doi.org/10.2174/011573403X404659250702080410","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to investigate the impact of different double-stent methods on the structure and mechanics of coronary bifurcation lesions, providing reference indicators for clinicians in selecting an appropriate interventional procedure.</p><p><strong>Methods: </strong>Three-dimensional reconstruction of coronary Computed Tomography Angiography (CTA) image data of a patient with coronary bifurcation disease was performed. Two types of double-stent (Cullotte and Crush) procedures were simulated, and their effects were evaluated using Finite element analysis. Intravascular Ultrasound (IVUS) validation and retrospective clinical analysis were performed to support computational findings.</p><p><strong>Results: </strong>The stress distribution following the Cullotte stent was concentrated in the SB, whereas the stress after the Crush procedure was localized at the overlap with the proximal main vessel three-layer stent. Compared with the Crush procedure, the Culotte approach resulted in a lower percentage of double-stent malapposition, better dilation of vascular stenosis, and less narrowing of the SB stent, suggesting a more favorable clinical outcome. IVUS validation and retrospective clinical analysis were performed to support computational findings.</p><p><strong>Discussion: </strong>Culotte stenting resulted in better stent-vessel conformity and more favorable stress distribution. The findings support FEA as a valuable tool in procedural planning.</p><p><strong>Conclusions: </strong>The findings suggest that the Culotte technique may offer mechanical advantages over the Crush technique, potentially improving long-term clinical outcomes. These results emphasize the role of computational modeling in optimizing interventional strategies.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal and Geographical Disparities in Amyloid and Heart Failure-Related Mortality: An Epidemiological Study 1999-2020.","authors":"Hoang Nhat Pham, Ramzi Ibrahim, Thi Nguyen, Enkhtsogt Sainbayar, Mahek Shahid, João Paulo Ferreira, Amitoj Singh, Kwan Lee, W H Wilson Tang, Preethi William","doi":"10.2174/011573403X374069250630105650","DOIUrl":"https://doi.org/10.2174/011573403X374069250630105650","url":null,"abstract":"<p><strong>Introduction: </strong>Amyloidosis complicated by heart failure (HF) poses significant mortality. We sought to identify trends in comorbid amyloidosis and HF mortality in the recent 22- year period.</p><p><strong>Methods: </strong>Mortality due to amyloid and HF as contributors of death were queried from death certificates using the CDC database from 1999 to 2020. Mortality rates and their 95% confidence intervals were adjusted for age (AAMR) through the Direct method and compared by demographic subpopulations. The Monte-Carlo permutation test was used to estimate the annual percentage change (APC). Log-linear regression models were utilized to assess temporal variation in mortality.</p><p><strong>Results: </strong>Age-adjusted mortality rates (AAMR) increased from 0.09 [0.08-0.10] in 1999 to 0.27 [0.25-0.29] in 2020. Mortality increased from 1999 to 2013 (APC +1.4, p=0.048) with an accelerating inflection point in 2013 to 2020 (APC +13.3, p<0.001). AAMR was higher among male populations (AAMR 0.20 [0.20-0.21]) compared to female populations (AAMR 0.07 [0.07- 0.07]). A significant inflection point in uprising mortality rates was observed for both male and female populations in 2013 (p<0.001). Mortality was highest among Black populations (AAMR 0.33), followed by White (AAMR 0.10), Asian/Pacific Islander (AAMR 0.06), and American Indian/Alaska Native populations (AAMR 0.04). Among Black populations, mortality remained consistent from 1999 to 2012 (APC +1.1, p=0.184), followed by an increase from 2012 to 2020 (APC +14.0, p<0.001). Among White populations, mortality remained stagnant from 1999 to 2013 (APC +0.7, p=0.302), followed by an increase starting in 2013 to 2020 (APC +13.5, p<0.001).</p><p><strong>Discussion: </strong>Our findings of a marked rise in HF-related mortality in patients with amyloidosis since 2013 highlighted the profound impact of enhanced diagnostic awareness, novel imaging techniques, and emerging therapeutics. Our analysis also showed mortality disparities between sexes, and geographic locations, races, and ethnicity that warrant targeted public health interventions.</p><p><strong>Conclusions: </strong>Amyloid and HF mortality increased in the recent 22-year period, primarily starting in 2013, emphasizing the urgent need for targeted intervention to address these disparities.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Uric Acid Levels and Risk of Atrial Fibrillation in Heart Failure Patients.","authors":"Mounika Reddy Vadiyala, Jeffy Varghese, Kesar Prajapati, Qiming Dong, Rupak Desai","doi":"10.2174/011573403X379855250620115105","DOIUrl":"https://doi.org/10.2174/011573403X379855250620115105","url":null,"abstract":"","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Transplantation: Immunological Challenges Revisited.","authors":"Sara Assadiasl, Sepehr Safdel, Mahsa Gheitasi, Mohammad Hossein Nicknam","doi":"10.2174/011573403X362826250619112705","DOIUrl":"https://doi.org/10.2174/011573403X362826250619112705","url":null,"abstract":"<p><strong>Introduction: </strong>Immunologic responses to cardiac allografts initiate before transplantation during brain-dead organ procurement and might persist for years after transplantation, culminating in chronic allograft dysfunction. Despite remarkable advances in post-transplant care and immunosuppressive agents, acute cellular and antibody-mediated rejections as well as chronic allograft vasculopathy significantly affect cardiac allograft and patient survival.</p><p><strong>Methods: </strong>Herein, recent findings of the molecular mechanisms involved in the inflammatory responses before and after heart transplantation, including brain death donor inflammation, acute cellular rejection, antibody-mediated rejection, and chronic allograft dysfunction, have been summarized, along with novel therapeutic approaches for their treatment. Finally, recent developments in prognostic and diagnostic biomarkers for immunological complications have been provided, with an overview of the most promising biomarkers to date.</p><p><strong>Results: </strong>Due to the recent developments in the description of molecular mechanisms involved in the immunopathogenesis of cardiac allograft rejection, some immune cells, proinflammatory cytokines, and adhesion molecules have been proposed as therapeutic targets for the prevention or treatment of alloimmune responses. In addition, several molecules derived from graft tissue or immune cells, e.g. natriuretic peptides, cardiac troponins, exosomal products, microRNAs, and donor-derived cell-free DNA, have been suggested as potential biomarkers for the prediction or diagnosis of cardiac transplant rejection.</p><p><strong>Conclusion: </strong>Considering the need to design non-invasive, low-cost tests for early diagnosis of post-transplant complications and convenient follow-up of the cardiac transplant recipients, peripheral blood biomarkers could be appropriate candidates for this purpose.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bibliometric Analysis of P2X7R in Cardiovascular Diseases From 2005 to 2024.","authors":"Juanjuan Tan, Wenqi Zhou, Zhiye Guo, Li Cheng, Yalong Kang, Qiong Wang, Jing Dong, Haifang Wang, Qi Zhang, Li Shen, Kai Huang","doi":"10.2174/011573403X376830250619055153","DOIUrl":"https://doi.org/10.2174/011573403X376830250619055153","url":null,"abstract":"<p><strong>Introduction: </strong>The P2X7 receptor (P2X7R), which mediates inflammation, is implicated in an extensive variety of diseases, including cardiovascular dysfunction. Recently, studies focusing on the role of P2X7R in cardiovascular disorders have garnered significant attention. However, a bibliometric evaluation within this area has yet to be carried out.</p><p><strong>Methods: </strong>A bibliometric analysis was performed by searching for research related to P2X7R and cardiovascular diseases in the Web of Science Core Collection (WoSCC) database from 2005 to 2024. The tools CiteSpace and VOSviewer were utilized to analyze data and create visual representations of various elements, including countries, institutions, authors, journals, and keywords.</p><p><strong>Results: </strong>Over the past two decades, 371 articles in English were obtained in the last 20 years. The People's Republic of China, Nanchang University, the journal 'Purinergic Signalling,' and author Shandong Liang had the highest productivity in their respective categories. The top 4 keywords were ''activation,'' ''p2x7 receptor,'' ''ATP,'' and ''inflammation''. Burst keyword analysis indicated that ''purinergic signaling'' and ''oxidative stress'' are emerging key areas worthy of further investigation. These topics, seeing a surge in interest, are predicted to remain prominent in research.</p><p><strong>Discussion: </strong>This is the first bibliometric analysis of P2X7R in cardiovascular disorders, which reports the hot spots and emerging trends. The interaction between ''purinergic signaling,'' ''inflammation,'' and ''oxidative stress'' are considered to be the current research priorities, suggesting that these topics are likely to remain central in future research.</p><p><strong>Conclusion: </strong>This study underscores the growing importance of P2X7R in cardiovascular research and offers valuable insights to guide future investigations.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytoconstituents-Mediated Targeting of Ferroptosis for the Treatment of Cardiovascular Disease.","authors":"Parul Gupta, Anjali Sharma, Sachin, Shubham Sharma, Devkant Sharma","doi":"10.2174/011573403X370981250618074406","DOIUrl":"https://doi.org/10.2174/011573403X370981250618074406","url":null,"abstract":"<p><p>Ferroptosis, an instance of iron-dependent programmable cell death that results from oxidative stress & lipid peroxidation, has garnered interest due to its associations with cardiovascular diseases, such as atherosclerosis, myocardial infarction, as well as heart failure. Unlike necrosis or apoptosis, ferroptosis involves unique metabolic pathways that disrupt cellular redox balance and lipid homeostasis, leading to substantial cell damage in cardiovascular tissues. It is becoming recognized that phytoconstituents-bioactive compounds derived from plants-can modify ferroptosis pathways and provide cardioprotective advantages. Compounds including curcumin, resveratrol, quercetin, tanshinone IIA, and epigallocatechin gallate (EGCG) have shown potential in preclinical studies by concentrating on significant ferroptotic processes. Finally, by controlling iron homeostasis, boosting antioxidant responses (such as Nrf2 pathway activation), and reducing lipid peroxidation, these phytochemicals may mitigate ferroptosisinduced cardiac cell death. In animal studies, these natural compounds have shown promise in reducing oxidative damage and improving heart function after injury. This article summarises the mechanisms via which a variety of phytoconstituents influence ferroptosis and discusses their potential as an adjuvant treatment for CVD. While these findings are encouraging, further research is needed to use them in clinical settings, with a focus on long-term safety in human populations, optimal dose, and absorption. The cardioprotective properties of phytoconstituents, which focus on ferroptosis, may provide a unique, plant-based therapeutic strategy for the treatment of CVDs.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial-Derived Peptides as Therapeutics and Biomarkers for Combating Vascular Aging and Associated Cardiovascular Diseases.","authors":"Rooban Sivakumar, K A Arul Senghor, V M Vinodhini, Janardhanan Kumar","doi":"10.2174/011573403X375709250616134726","DOIUrl":"https://doi.org/10.2174/011573403X375709250616134726","url":null,"abstract":"<p><p>Vascular aging profoundly affects the onset of cardiovascular diseases in the elderly, mostly as a result of mitochondrial dysfunction. This review examines the protective roles of mitochondrial-derived peptides such as humanin, MOTS-c, and small humanin-like peptides in mitigating vascular aging. These peptides, encoded by mitochondrial DNA, are crucial for regulating apoptosis, inflammation, and oxidative stress, which have a major role in vascular health. MDPs have significant prospects as therapeutic and biomarker possibilities for the early diagnosis and intervention of vascular aging. MDPs influence the functions of endothelial and vascular smooth muscle cells by modulating critical signaling pathways, including AMPK, mTOR, and sirtuins. These pathways are essential for facilitating cellular metabolism, enhancing stress resilience, and prolonging longevity. Moreover, MDPs are essential in mitochondrial bioenergetics and dynamics, vital for mitigating endothelial dysfunction and enhancing vascular resilience. Furthermore, MDPs contribute to immunological modulation and the regulation of inflammatory responses, underscoring their potential therapeutic applications in the treatment of age-related vascular disorders. This review analyzes the various functions of MDPs in vascular health and their therapeutic importance, advocating for more studies to optimize their clinical benefits. By understanding the comprehensive roles and mechanisms of these multifunctional peptides, we can better appreciate their capacity to prevent and treat vascular aging and associated cardiovascular disorders. Future research should aim to further elucidate their therapeutic effects and optimize their clinical applications.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blockchain and NFTs in Cardiovascular Health Record Management: Enhancing Security, Privacy, and Patient-Centric Care.","authors":"Moiud Mohyeldin, Vanisa Ezukuse, Udesh Pandey, Feras O Mohamed, Ahmed Mg Mustafa, Muhanned Towfig, Ahmed Abdelghafar, Faris Alamin, Ashraf Ahmed, Misbahuddin Khaja","doi":"10.2174/011573403X358483250616063810","DOIUrl":"https://doi.org/10.2174/011573403X358483250616063810","url":null,"abstract":"<p><strong>Background: </strong>The management of cardiovascular health records faces significant challenges, including data fragmentation, security vulnerabilities, and interoperability barriers. Blockchain and Non-Fungible Tokens (NFTs) are emerging technologies with the potential to revolutionize healthcare data management by enhancing security, transparency, and patient empowerment. These innovations aim to address systemic inefficiencies, providing a robust framework for data integrity and patient-centric care.</p><p><strong>Objectives: </strong>This study explores the integration of blockchain and NFTs into cardiovascular health record management, focusing on their potential to enhance security, improve efficiency, and empower patients. It also examines systemic barriers and proposes solutions to facilitate widespread adoption.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted using PubMed, IEEE Xplore, and Google Scholar databases. Search terms included \"blockchain,\" \"NFTs,\" \"health records,\" and \"cardiovascular care.\" Inclusion criteria prioritized peer-reviewed articles published between 2015 and 2025 that addressed technical challenges, cases of real-world implementation, and innovative solutions. Articles lacking technical depth or relevance to health records were excluded. Data were categorized into themes such as security, privacy, interoperability, and patient empowerment.</p><p><strong>Results: </strong>Blockchain ensures data integrity through a decentralized ledger, while NFTs enable patient-controlled access to health records. Smart contracts streamline workflows, fostering interoperability. Key challenges include scalability, regulatory compliance, and integration with existing systems. Emerging solutions, such as hybrid blockchain models and cryptographic advancements, address these barriers. Case studies demonstrate real-world applications, underscoring the transformative potential of these technologies.</p><p><strong>Conclusions: </strong>Blockchain and NFTs offer groundbreaking opportunities for managing cardiovascular health records, emphasizing security, privacy, and patient-centric care. Addressing technical and regulatory challenges through targeted research and development is essential for their adoption. These technologies signify a paradigm shift in healthcare, promoting seamless interoperability and improved patient outcomes.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis.","authors":"André Saad Cleto, João Matheus Schirlo, Janete Machozeki, Camila Marinelli Martins","doi":"10.2174/011573403X357542250526072430","DOIUrl":"https://doi.org/10.2174/011573403X357542250526072430","url":null,"abstract":"<p><strong>Introduction: </strong>The PCSK9 enzyme is present mainly in the liver and is responsible for the degradation of LDL-C receptors. Currently, there are some drugs that inhibit this enzyme, such as alirocumab and evolocumab. Consequently, these drugs reduce serum LDL-C levels. Therefore, a systematic review and a meta-analysis were carried out in order to compare alirocumab against evolocumab in reducing cardiovascular outcomes.</p><p><strong>Methods: </strong>This systematic review was carried out in accordance with PRISMA and was registered in PROSPERO (CRD42024573217). The following databases were searched on July, 9, 2024: Pubmed, Web of Science and Scopus. Randomized clinical trials with a control group were included and meta-analyses were performed to assess relative risk (RR). The random effects model was used in heterogeneous samples. The articles were distributed into 2 subgroups: use of alirocumab and evolocumab.</p><p><strong>Results: </strong>Initially, 2,213 articles were found, of which 6 were included. In total, 62,119 patients participated. The RR values were significant for alirocumab in the following outcomes: myocardial infarction (MI) 0.85 (95% CI 0.77-0.93), stroke 0.75 (95% CI 0.60-0.94) and hospitalization for unstable angina 0.58 (95% CI 0.39-0.86), while for evolocumab they were significant for MI 0.75 (95% CI 0.68-0.83) and coronary revascularization 0.81 (95 CI % 0.75-0.88). There was a statistically significant difference between the drugs for hospitalization for unstable angina (p=0.02).</p><p><strong>Discussion: </strong>This study highlights the benefits of PCSK9 inhibitors, especially alirocumab, in reducing major cardiovascular events. Alirocumab significantly lowered hospitalizations for unstable angina, with a 42% reduction, and showed favorable outcomes in reducing myocardial infarction, coronary revascularization, and stroke. These reductions are clinically meaningful, as they lower morbidity, improve patient quality of life, and reduce healthcare costs. Both alirocumab and evolocumab are effective and safe, offering important therapeutic options for high-risk cardiovascular patients.</p><p><strong>Conclusion: </strong>The use of alirocumab is preferable if the focus is to avoid hospitalizations for unstable angina or stroke, while evolocumab may be an option if one wants to avoid coronary revascularization. Both drugs are effective in reducing cardiovascular outcomes, but alirocumab was superior to evolocumab.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of Hemodynamics and Quality of Life Before and After Interatrial Shunt Devices Implantation for Chronic Heart Failure: A Systematic Review and Meta-analysis.","authors":"Yugen Guan, Lei Yang, Yuwen Lu, Xiaogan Liang, Ruiqi Wang, Rongrong Shen, Liang Yang, Jingwen Song, Shaofei Liu, Yuan Bai, Zhifu Guo, Ni Zhu","doi":"10.2174/011573403X376422250522094942","DOIUrl":"https://doi.org/10.2174/011573403X376422250522094942","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to compare the quality of life and hemodynamic changes before and after transcatheter atrial septal shunt implantation.</p><p><strong>Methods: </strong>A systematic search was conducted in the Cochrane Library, PubMed, and Embase from inception to September 2023 for studies reporting on hemodynamics or quality of life in patients with chronic heart failure after atrial septal shunt implantation. A meta-analysis was performed, in which a total of 1026 participants from 13 articles were included.</p><p><strong>Results: </strong>Following the implantation, pulmonary capillary wedge pressure (PCWP) decreased by 2.60 mmHg. Right atrial pressure (RAP) increased by 1.30 mmHg and left ventricular ejection fraction (LVEF) increased by 2.13%. However, there were no significant differences in cardiac output and mean pulmonary artery pressure (mPAP) after operation. Minnesota Living with Heart Failure (MLWHF) Score decreased by -19.28, while the Kansas City Cardiomyopathy Questionnaire (KCCQ) score increased by 25.41. Moreover, 6-minute walking distance (6MWD) increased by 32.22 m. The results of subgroup analysis showed that for patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF), LVEF increased by 3.09% while CO increased by 1.01 L/min after operation. Meanwhile, PCWP significantly decreased by 2.67 mmHg and MLWHF scores decreased by 19.28. Additionally, 6MWD significantly increased by 27.5 m. However, there were no significant changes in RAP and mPAP after operation. For patients with heart failure with reduced ejection fraction (HFrEF), interatrial shunt device implantation did not achieve a significant increase in LVEF.</p><p><strong>Conclusion: </strong>These findings suggest that while atrial septal shunt implantation might not yield LVEF elevation among patients with HFrEF, it improves hemodynamic parameters, exercise endurance, and QoL among individuals with HFpEF/HFmrEF.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}